Biotechnology innovator BiondVax Pharmaceuticals (NASDAQ: BVXV) recently provided a business update, published its full-year financial results for the period ended December 31, 2022, and filed its annual report on Form 10-K with the Securities and Exchange Commission (“SEC”) (https://ibn.fm/GsIVG). The business update reflected recent highlights and achievements that company CEO Amir Reichman says leave him […]
The Stocks To Buy Now Blog
Our team has been covering the micro- and small-cap markets for more than a decade, exploring a wide variety of trends, technology and news in every industry. The Stocks to Buy Now blog seeks out undervalued companies, covers their news, breaks down the jargon, and delivers accurate and timely information to you on a daily basis.